AEGON ASSET MANAGEMENT UK Plc Has $23.55 Million Stock Position in Insulet Corporation $PODD

AEGON ASSET MANAGEMENT UK Plc lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 17.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 76,274 shares of the medical instruments supplier’s stock after selling 15,767 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc owned approximately 0.11% of Insulet worth $23,547,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of PODD. Sage Mountain Advisors LLC grew its stake in shares of Insulet by 4.6% during the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 33 shares during the last quarter. Curi Capital LLC raised its position in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the last quarter. Evelyn Partners Investment Management Services Ltd lifted its holdings in Insulet by 28.7% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 39 shares in the last quarter. PDS Planning Inc boosted its position in Insulet by 5.1% in the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock valued at $253,000 after buying an additional 40 shares during the last quarter. Finally, Camarda Financial Advisors LLC boosted its position in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after buying an additional 40 shares during the last quarter.

Insulet Stock Performance

Shares of Insulet stock opened at $271.57 on Monday. The stock’s fifty day simple moving average is $298.48 and its 200 day simple moving average is $310.34. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $19.10 billion, a PE ratio of 78.72, a PEG ratio of 1.51 and a beta of 1.40. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The company’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.08 earnings per share. On average, research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PODD. Canaccord Genuity Group boosted their target price on Insulet from $432.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research report on Thursday. Rothschild & Co Redburn upped their target price on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Leerink Partners raised their target price on shares of Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Finally, Wells Fargo & Company boosted their price target on shares of Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $379.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.